Study Finds Common Supplements Could Rival Antibiotics Against Severe Gum Disease

A yearlong clinical trial suggests that omega-3 fatty acids combined with low-dose aspirin may help treat severe gum disease nearly as effectively as antibiotics, potentially offering an alternative for selected patients and reducing unnecessary antibiotic use.

Published in the Journal of Periodontology, the study involved 109 people with advanced periodontitis. All participants received scaling to remove bacterial deposits from beneath the gums and were then randomly assigned to different treatment groups.

One group received the antibiotics metronidazole and amoxicillin for 14 days, while another received 3 grams of omega-3 daily plus low-dose aspirin for six months. A third group received both treatments, and the control group received placebos.

After one year, 58% of patients receiving antibiotics achieved the study's treatment target—having no more than four remaining deep periodontal pockets. The omega-3 and aspirin group performed almost identically, with 57.7% reaching the same target.

By comparison, only 23.1% of patients receiving scaling plus placebo achieved the target.

Interestingly, combining antibiotics with omega-3 and aspirin did not provide additional benefit compared with either approach alone.

Researchers believe omega-3 may work by helping the body produce molecules that naturally resolve inflammation and support tissue repair, while low-dose aspirin may enhance this process.

The apparent benefits also persisted after supplementation stopped, with patients continuing to show similar outcomes six months later.

The findings could be particularly relevant as antibiotic resistance becomes a growing global health concern. An omega-3–based approach could potentially provide an option for patients who cannot tolerate antibiotics or in situations where antibiotics may be avoided.

However, researchers emphasize that omega-3 and aspirin should not yet replace antibiotics routinely. More studies are needed to confirm the findings in larger, more diverse populations and determine which patients are most likely to benefit.

REFERENCE: Nidia C. Castro dos Santos, et al.; Immunomodulators, associated or not with systemic antibiotics, to treat periodontitis: A 1‐year multicenter, placebo‐controlled, double‐blind, randomized clinical trial. Journal of Periodontology, 2026; 97 (7): 1454 DOI: 10.1002/jper.70081